PORTLAND, Maine–(BUSINESS WIRE)–MedRhythms, a leader in developing prescription digital therapeutics that use sensors, software, and music to measure and improve walking for patients with a neurologic injury or disease, today announced the closing of a Series B extension round, with investment from one of Japan’s largest venture capital companies Global Brain with its CVC JGC MIRAI Innovation Fund, and Bose Ventures. The follow-on investment brings the Company’s total Series B financing to $27 million, an increase from their announcement in July. Read more
MedRhythms Announces Addition of Global Brain Corporation and Bose Ventures to Series B Round
Related Posts
Bangor will be abuzz with Maine science at annual festival
The Maine Science Festival’s headlining event will be a major collaboration with a local arts organization for the second year in...
Report: National Institutes of Health added $264M to Maine economy in 2022
The National Institutes of Health supported 1,950 jobs and $264 million in economic activity in Maine during 2022 through $112.7 million in grants and...
Northern Light completes deal to outsource diagnostics to Quest
Quest Diagnostics (NYSE: DGX), a Secaucus, N.J.-based diagnostic information services provider with a national footprint, said Monday that it has completed the acquisition...